Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.

van Kempen ZLE, Leurs CE, de Vries A, Vennegoor A, Rispens T, Wattjes MP, Killestein J.

Eur J Neurol. 2017 Sep;24(9):1196-1199. doi: 10.1111/ene.13355. Epub 2017 Jul 14.

PMID:
28707781
2.

Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.

van Kempen ZL, Leurs CE, Vennegoor A, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.

Mult Scler. 2017 Jun;23(7):995-999. doi: 10.1177/1352458516684023. Epub 2016 Dec 13.

PMID:
28112019
3.

Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site.

van Schie KA, Kruithof S, van Schouwenburg PA, Vennegoor A, Killestein J, Wolbink G, Rispens T.

J Allergy Clin Immunol. 2017 Mar;139(3):1035-1037.e6. doi: 10.1016/j.jaci.2016.09.014. Epub 2016 Oct 4. No abstract available.

PMID:
27717666
4.

MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.

Wijburg MT, Witte BI, Vennegoor A, Roosendaal SD, Sanchez E, Liu Y, Martins Jarnalo CO, Uitdehaag BM, Barkhof F, Killestein J, Wattjes MP.

J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1138-45. doi: 10.1136/jnnp-2016-313772. Epub 2016 Aug 16.

PMID:
27530808
5.

High cumulative JC virus seroconversion rate during long-term use of natalizumab.

Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JL, Uitdehaag BM, Killestein J.

Eur J Neurol. 2016 Jun;23(6):1079-85. doi: 10.1111/ene.12988. Epub 2016 Mar 27.

PMID:
27018481
6.

Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.

Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, Roosendaal SD, Sanchez E, Liu Y, Martins Jarnalo CO, Richert ND, Uitdehaag BM, Barkhof F, Killestein J.

Mult Scler. 2016 Aug;22(9):1174-83. doi: 10.1177/1352458515615225. Epub 2015 Nov 12.

PMID:
26564995
7.

MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.

Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, de Vos M, Richert ND, Uitdehaag BM, Barkhof F, Killestein J; Dutch-Belgian Natalizumab-associated PML study group.

J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):879-84. doi: 10.1136/jnnp-2015-311411. Epub 2015 Sep 14.

PMID:
26369555
8.

Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.

Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J.

Mult Scler. 2015 Oct;21(12):1600-3. doi: 10.1177/1352458514567728. Epub 2015 Feb 6.

PMID:
25662344
9.

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation.

Killestein J, Vennegoor A, van Golde AE, Bourez RL, Wijlens ML, Wattjes MP.

Case Rep Neurol Med. 2014;2014:307872. doi: 10.1155/2014/307872. Epub 2014 Nov 23.

10.

MRI pattern in asymptomatic natalizumab-associated PML.

Wattjes MP, Vennegoor A, Steenwijk MD, de Vos M, Killestein J, van Oosten BW, Mostert J, Siepman DA, Moll W, van Golde AE, Frequin ST, Richert ND, Barkhof F.

J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):793-8. doi: 10.1136/jnnp-2014-308630. Epub 2014 Sep 9.

PMID:
25205744
11.

The effect of prolonged natalizumab treatment on anxiety and safety in JC virus-seropositive MS patients; a follow-up study.

van Rossum JA, Vennegoor A, Killestein J.

Mult Scler. 2014 Oct;20(12):1668-9. doi: 10.1177/1352458514543341. Epub 2014 Aug 11. No abstract available.

PMID:
25112817
12.

Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.

Vennegoor A, Rispens T, Van Oosten BW, Wattjes MP, Wondergem MJ, Teunissen CE, Van der Kleij D, Uitdehaag BM, Polman CH, Killestein J.

Mult Scler. 2015 Apr;21(4):481-4. doi: 10.1177/1352458514541507. Epub 2014 Jul 30.

PMID:
25078275
13.

Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?

Wattjes MP, Vennegoor A, Mostert J, van Oosten BW, Barkhof F, Killestein J.

J Neurol. 2014 Jun;261(6):1139-43. doi: 10.1007/s00415-014-7336-5. Epub 2014 Apr 6.

PMID:
24705790
14.

The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA.

Koel-Simmelink MJ, Vennegoor A, Killestein J, Blankenstein MA, Norgren N, Korth C, Teunissen CE.

J Immunol Methods. 2014 Jan 15;402(1-2):43-9. doi: 10.1016/j.jim.2013.11.008. Epub 2013 Nov 22.

PMID:
24275679
15.

Drug interference in immunogenicity assays depends on valency.

Rispens T, Hart MH, Ooijevaar-de Heer P, van Leeuwen A, Vennegoor A, Killestein J, Wolbink GJ, van der Kleij D.

J Pharm Biomed Anal. 2013 Nov;85:179-85. doi: 10.1016/j.jpba.2013.07.022. Epub 2013 Jul 30.

PMID:
23954437
16.

Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients.

van Rossum JA, Vennegoor A, Balk L, Uitdehaag BM, Polman CH, Killestein J.

Mult Scler. 2014 Jan;20(1):108-11. doi: 10.1177/1352458513495582. Epub 2013 Jul 4.

PMID:
23828867
17.

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.

Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, Barkhof F, Polman CH, Wolbink G, Killestein J.

Mult Scler. 2013 Apr;19(5):593-600. doi: 10.1177/1352458512460604. Epub 2012 Sep 19.

PMID:
22992450
18.

Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.

Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J.

Mult Scler. 2012 Jun;18(6):899-901. doi: 10.1177/1352458511431073. Epub 2011 Dec 19.

PMID:
22183929
19.

Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients.

Ketelslegers IA, Modderman PW, Vennegoor A, Killestein J, Hamann D, Hintzen RQ.

Mult Scler. 2011 Dec;17(12):1527-30. doi: 10.1177/1352458511412995. Epub 2011 Aug 9.

PMID:
21828202
20.

Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.

Vennegoor A, Wattjes MP, van Munster ET, Kriekaart RL, van Oosten BW, Barkhof F, Killestein J, Polman CH.

Neurology. 2011 Feb 8;76(6):574-6. doi: 10.1212/WNL.0b013e31820b7644. No abstract available.

PMID:
21300973

Supplemental Content

Loading ...
Support Center